Recent Media
Forward Looking Statements
The Company makes certain filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission (the “SEC”), all of which are available under our profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. For a more complete discussion of the risk factors affecting our business, please refer to these filings.
Our public communications, including this media page, SEDAR+ and SEC filings may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as “believes,” “estimates,” “anticipates,” “targets,” “expects,” “plans,” “projects,” “intends,” “predicts,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
=============================================================================================================
2026 July – Dr. Williams, BriaCell CEO, featured in Yahoo Finance (Simply Wall Street pick-up)
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
=============================================================================================================
2026 July – Dr. Williams, BriaCell CEO, featured in Simply Wall Street
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
=============================================================================================================
2026 July – Dr. Williams, BriaCell CEO, featured in The Canadian Business Journal
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
=============================================================================================================
2026 July – Dr. Williams, BriaCell CEO, featured in PharmaSource
BriaCell Therapeutics Partners with FUJIFILM Biotechnologies California for Phase 3 Bria-IMT Manufacturing
=============================================================================================================
2026 July – Dr. Williams, BriaCell CEO, featured in Contract Pharma
BriaCell Taps FUJIFILM for Bria-IMT Manufacturing
=============================================================================================================
2026 July
Immune Engineering: The Next Revolution in Cancer Immunotherapy | Dr. William Williams – BriaCell
=============================================================================================================
2026 July
Dr. Williams interview on the Nano Cap Podcast
=============================================================================================================
2026 July
Dr. Williams’ Q&A feature with BioPharma Boardroom
=============================================================================================================
2026 July
BriaCell Presentation – by Renmark Financial
=============================================================================================================
2026 March
Watch Dr. Kelly McCann, MD, PhD, Hematologist, Oncologist, UCLA Health, to learn more about BRIA-ABC, BriaCell’s pivotal Phase 3 clinical study evaluating Bria-IMT plus an immune check point inhibitor in metastatic breast cancer.
=============================================================================================================
2025 December – Nature Medicine – Eleven clinical trials that will shape medicine in 2026
BriaCell Phase 3 Trial Featured in Nature Medicine
=============================================================================================================
2025 June – Oncology Central –ASCO insights: Bria-IMT + checkpoint inhibitor trials in metastatic breast cancer
Dr. Carmen Calfa, Principal Clinical Investigator of the Phase 2 Bria-IMT study, is featured to discuss BriaCell Poster presentation at ASCO25 which highlighted survival results for Bria-IMT + checkpoint inhibitors for metastatic breast cancer (MBC) patients
=============================================================================================================
2024 October – OncLive – Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis
Dr. Giuseppe Del Priore, BriaCell’s CMO, and Dr. William V. Williams, BriaCell’s CEO, are featured to discuss BriaCell reporting of 100% Resolution of brain metastasis in breast cancer patient with “eye-bulging” tumor
=============================================================================================================
2024 September – OncLive – BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer
Principal Investigator, and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, and BriaCell’s Medical Advisory Board Member, and Professor of Medicine at the University of Pittsburgh School of Medicine, Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer
=============================================================================================================
